Psychedelic Alpha’s Josh Hardman sat down with Beckley Psytech CEO Cosmo Feilding-Mellen and Chief Scientific and Medical Officer Rob Conley to discuss today’s topline results from the company’s Phase 2b trial of intranasal 5-MeO-DMT (BPL-003) in treatment-resistant depression (TRD). Before you dive into this interview, be sure to read our headline coverage of the results: BREAKING: Beckley’s 5…
